Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates

06 Oct 2016

• By Sukaina Virji

Teva is looking to tap into $6.5bn in US sales of Herceptin and Rituxan in a new deal for North American rights to two of Celltrion's pipeline biosimilars for $160m upfront.

Teva Pharmaceutical Industries Ltd. has signed a deal to commercialize two of Celltrion Inc.'s monoclonal antibody (mAb) biosimilar candidates in the US and Canada. Celltrion's CT-P10 is a proposed biosimilar to Rituxan (rituximab) and CT-P6 is a biosimilar candidate to Herceptin (trastuzumab).

The agreement is exactly what Teva's Global Generic Medicines CEO Sigurdur Olafsson said he was looking for in a recent investor meeting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

12 May 2025

• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.